URGN
Urogen Pharma Ltd.
A biotech whose gel turns liquid to jelly at body heat, letting cancer drugs linger in the urinary tract for hours instead of minutes. Its FDA-approved treatments Jelmyto and Zusduri offer non-surgical options for rare bladder and kidney-tube cancers. Born in 2004 as Theracoat, it renamed itself UroGen in 2015 and won its first approval in 2020.
CINS: M96088105ISIN: IL0011407140HealthcareIL2 holders
Total Value
$4.23M
Total Shares
334.2K
Net Share Change
-37.4K
Activity
2 selling
Investor
Value
Shares
Weight
Change
